IP Library Granted Patent US 10,973,799
Granted Patent B2
US 10,973,799 · App. 16/444,981 · Granted Apr 13, 2021

Isoflavonoid compositions and methods for the treatment of cancer

Inventor: Ofir Moreno (Poway, CA)
Assignee: MEI PHARMA, INC.
A61K31/353A61K9/0019A61K9/5161A61K31/337A61K31/555A61K33/24A61K45/06A61K47/40C07D311/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,799
App. No.
16/444,981
Granted
Apr 13, 2021
Kind
B2
Abstract

Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.

Claims (9)

1. A method of treating breast cancer in an individual in need, the method comprising administering to the individual a composition comprising: i) d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol provided in at least 90% enantiomeric excess and ii) a cyclodextrin.

2. The method of claim 1 , wherein the cyclodextrin is SBE7-β-CD.

3. The method of claim 1 , wherein the cyclodextrin has a concentration (w/v) ranging from about 0.001% to about 50%.

4. The method of claim 1 , wherein the composition further comprises water.

5. The method of claim 1 , wherein the composition further comprises one or more of lactose, dextrose, mannitol, a pH buffering agent, an antioxidant agent, a preservative agent, a tonicity adjuster, or a combination thereof.

6. The method of claim 1 , wherein the composition comprises d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol in an amount of about 0.2-50 mg/mL.

7. The method of claim 1 , wherein the breast cancer is metastatic breast cancer.

8. The method of claim 1 , wherein the breast cancer is metastatic HER2-negative breast cancer.

9. The method of claim 1 , wherein the breast cancer has lost sensitivity to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: MEI PHARMA, INC
To: AARDVARK THERAPEUTICS, INC.
Reel/Frame 069421/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2019
From: MORENO, OFIR
To: MARSHALL EDWARDS, INC.
Reel/Frame 049511/0789 →
MERGER AND CHANGE OF NAME Recorded Jun 18, 2019
From: MEI PHARMA, INC.; MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 049511/0949 →
Continuity (5)
Continuation 15961259 · Apr 24, 2018
Continuation 15622569 · Jun 14, 2017
Continuation 13881599
Provisional Application 61408972 · Nov 1, 2010
Related Publication 20200121635A1 · Apr 23, 2020
Cited By (3)
US 12,318,364 US 12,329,739 US 12,414,934